Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

Figure 4

Effect of PLK1 inhibition on breast cancer cell growth, apoptosis, and TICs. (A) Percentage of growth inhibition of different breast cancer cells by a PLK1 small-molecule inhibitor BI 2536 at different concentrations for 72 hours. C, control (medium only). D, dimethyl sulfoxide only. (B) Percentage of growth inhibition of SUM149 cells by BI 2536 at different concentrations for 10 days. (C) Percentage of growth inhibition of sorted CD44high/CD24-/low of SUM149 by BI 2536 for 72 hours. (D) Percentage of mammosphere reduction in SUM149 and MDA-MB-231 by BI 2536. *Significant difference from the control (Student t test, P < 0.05). (E) Percentage of apoptosis of different breast cancer cells caused by BI 2536 after 72 hours. (F) Time-course apoptosis of SUM149 treated with BI 2536 for 6, 24, and 48 hours. (G) Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Data are presented as mean ± SD of two independent tests. TICs, tumor-initiating cells.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us